NCX 470

NCX 470 is a second-generation nitric oxide (NO)-donating prostaglandin analogue. NCX 470 effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. NCX 470 can be used for the research of cular hypertension and glaucoma. In Vivo NCX 470 shows a better intraocular pressure-lowering efficacy than that of equimolar doses of bimatoprost in well-established animal models of glaucoma and ocular hypertension . NCX 470 (0.14% 30 μL; instillation; once) reduces IOP in transient ocular hypertensive rabbits. NCX 470 (0.042% 30 μL; instillation; once) is more effective than equimolar bimatoprost in cynomolgus monkeys with laser-induced ocular hypertension (OHT-monkeys), and normotensive dogs (ONT-dogs) at 18 hours post dosing. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: New Zealand white rabbits with 0.1 mL 5% sodium chloride solution injectionDosage: 0.14% Administration: Instillation; 0.14% 30 μL; once Result: Significantly blunted the IOP rise throughout the experimental period in transiently ocular hypertensive New Zealand white rabbits.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet